Business Standard

GVK Bio partners US firm

BS Reporter  |  Chennai 

  • ALSO READ

    Nalco can gain Rs 250 cr on alumina sale to Vedanta

    Sesa Goa readies capex for Liberia project, shipments to begin from Feb'14

    Sesa Goa readies capex for Liberia project

    Mining ban: Sesa Goa defers 10-25% of salaries from Jan

    Fire breaks out in top Ahmedabad hotel

Hyderabad-based drug discovery research and development firm (GVK Bio) has entered into a collaboration agreement with US-based Endo Pharmaceuticals focused on discovering novel small molecules targeting a protein.

As per the agreement, GVK Bio will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialise the product arising out of this collaboration. The collaboration arose out of a newly-launched concept at GVK Bio named Early Discovery Assets (EDA).

GVK Bio partners US firm

Hyderabad-based drug discovery research and development firm GVK Biosciences (GVK Bio) has entered into a collaboration agreement with US-based Endo Pharmaceuticals focused on discovering novel small molecules targeting a protein.

Hyderabad-based drug discovery research and development firm (GVK Bio) has entered into a collaboration agreement with US-based Endo Pharmaceuticals focused on discovering novel small molecules targeting a protein.

As per the agreement, GVK Bio will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialise the product arising out of this collaboration. The collaboration arose out of a newly-launched concept at GVK Bio named Early Discovery Assets (EDA).

image

Latest News